Real-world evidence on the economic implications of CGRP-mAbs as preventive treatment of migraine

Real-world evidence on the economic implications of CGRP-mAbs as preventive treatment of migraine

Abstract Background Calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) are approved in Europe as preventive treatment of migraine in patients with at least four monthly migraine days. Migraine gives rise to direct healthcare expenditures, but most of the economic burden of migraine...

Full description

Bibliographic Details
Main Authors: Nikolaj Siersbæk, Lærke Kilsdal, Christian Jervelund, Sonja Antic, Lars Bendtsen
Format: Article
Language:English
Published: BMC 2023-07-01
Series:BMC Neurology
Subjects:
CGRP-mAbs
Real-world evidence
Socioeconomic gains
Health economic savings
Indirect cost
Direct cost
Online Access:https://doi.org/10.1186/s12883-023-03302-7

Internet

https://doi.org/10.1186/s12883-023-03302-7

Similar Items